These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39026664)

  • 61. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer.
    Sun J; Yue W; You J; Wei X; Huang Y; Ling Z; Hou J
    Front Oncol; 2021; 11():730716. PubMed ID: 34557413
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
    Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
    Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
    Sato E; Iriyama N; Tokuhira M; Takaku T; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Kimura Y; Fujioka I; Asou N; Komatsu N; Kizaki M; Hatta Y; Kawaguchi T
    Cancer Med; 2020 Dec; 9(23):8931-8939. PubMed ID: 33037866
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
    Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F
    Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Integrating machine learning algorithms and multiple immunohistochemistry validation to unveil novel diagnostic markers based on costimulatory molecules for predicting immune microenvironment status in triple-negative breast cancer.
    Zhang C; Zhai W; Ma Y; Wu M; Cai Q; Huang J; Zhou Z; Duan F
    Front Immunol; 2024; 15():1424259. PubMed ID: 39007147
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Machine learning-based identification and immune characterization of ferroptosis-related molecular clusters in osteoarthritis and validation.
    Guo X; Feng X; Yang Y; An W; Bai L
    Aging (Albany NY); 2024 May; 16(11):9437-9459. PubMed ID: 38814177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
    Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
    [TBL] [Abstract][Full Text] [Related]  

  • 69. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
    Adnan Awad S; Dufva O; Ianevski A; Ghimire B; Koski J; Maliniemi P; Thomson D; Schreiber A; Heckman CA; Koskenvesa P; Korhonen M; Porkka K; Branford S; Aittokallio T; Kankainen M; Mustjoki S
    Leukemia; 2021 Apr; 35(4):1087-1099. PubMed ID: 32782381
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
    Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
    Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Stem Cell Responsiveness to Imatinib in Chronic Myeloid Leukemia.
    Lahlil R; Aries A; Scrofani M; Zanetti C; Hennequin D; Drénou B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068992
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification and validation of an individualized prognostic signature of lung squamous cell carcinoma based on ferroptosis-related genes.
    Diao X; Guo C; Liu L; Wang G; Li S
    Thorac Cancer; 2021 Dec; 12(23):3236-3247. PubMed ID: 34672420
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
    Shen HJ; He J; Qiu QC; Cen JN; Pan JL; Yao L; Ding ZX; Chen Y; Chen ZX
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jan; 34(1):21-5. PubMed ID: 23597459
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study.
    Zhang H; Wang P; Song T; Bonnette UL; Zhang Z
    Hematology; 2021 Dec; 26(1):408-414. PubMed ID: 34053416
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia.
    Ozel B; Kipcak S; Biray Avci C; Sabour Takanlou M; Sabour Takanlou L; Tezcanli Kaymaz B; Karatekin I; Gunduz C; Selvi Gunel N
    Med Oncol; 2022 Jun; 39(9):126. PubMed ID: 35716222
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

  • 79. circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation.
    Wang J; Liang Y; Qin Y; Jiang G; Peng Y; Feng W
    J Transl Med; 2022 Sep; 20(1):395. PubMed ID: 36058922
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.